PathAI has received Breakthrough Device Designation from the FDA for its AI-driven dermatopathology solution, PathAssist Derm. This technology aids pathologists in evaluating digital images of skin lesions, enhancing diagnostic efficiency. PathAssist Derm analyzes whole slide images from biopsies, enabling prioritization of cases and structured assessments. This designation follows PathAI securing FDA 510(k) clearance for AISight Dx, a pioneering digital pathology image management system featuring an authorized Predetermined Change Control Plan for updating AI components. Additionally, PathAI’s AIM-MASH AI Assist has gained qualification from both the EMA and FDA as a vital tool for drug development research. CEO Dr. Andy Beck emphasized the significance of this breakthrough, reinforcing the company’s commitment to clinically validated AI tools in pathology, especially crucial in light of rising skin cancer incidences. As laboratories face increasing workloads, PathAI aims to collaborate with global regulatory bodies to enhance diagnostic confidence and patient care through advanced AI solutions.
Source link
